Supply Chain Intelligence

Ironwood Pharmaceuticals, Inc. Supply Chain

IRWD supply chain intelligence for Ironwood Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

IRWD ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
9Customers
3Debt Items
20Related Chains

Ironwood Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
FERRING-INTERNATIONAL-CENTER-S-A FERRING-INTERNATIONAL-CENTER-S-A 92% The Amendment provides for a payment by VectivBio of $12.5 million, in the aggregate, to Ferring
WELLS-FARGO-BANK-NATIONAL-ASSOCIATION WELLS-FARGO-BANK-NATIONAL-ASSOCIATION 90% On March 10, 2026, Ironwood Pharmaceuticals, Inc. (the “Company”) notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Agent”), under the Credit Agreement
NEUP Neuphoria Therapeutics Inc. 72% Reciprocal relationship from NEUP graph: obtain regulatory approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf or conduct sales and marketing activi…
ORANY ORANY 72% . Hanmi Pharmaceutical is also developing a GLP-2 analog, to be administered once a month, and which is being evaluated in a Phase II clinical trial. Products with other mechanisms of action may emer…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from IRWD graph: . Hanmi Pharmaceutical is also developing a GLP-2 analog, to be administered once a month, and which is being evalua…
ZLDPF Zealand Pharma A/S 72% example, for apraglutide, we compete with companies that are commercializing or developing drugs for SBS, such as Takeda, which currently distributes the GLP-2 analog teduglutide, marketed as GATTEX®…
ZLDPF Zealand Pharma A/S 72% Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD graph: example, for apraglutide, we compete with companies that are commercializing or developing drugs for SBS, such as Ta…

Ironwood Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
ABBV AbbVie Inc. 92% The Company records royalties on sales of CONSTELLA in Canada and LINZESS in Mexico in the period earned.
ABBV AbbVie Inc. 92% Reciprocal relationship from ABBV graph: Reciprocal relationship from IRWD graph: The Company records royalties on sales of CONSTELLA in Canada and LINZESS in Mexico in the period earned.
ASTELLAS-PHARMA-INC ASTELLAS-PHARMA-INC 92% Under the license agreement, as amended, Astellas is required to pay royalties to the Company at rates beginning in the mid-single digit percent and escalating to low-double-digit percent, based on a…
AZN AstraZeneca PLC 92% Under the collaboration agreement, AstraZeneca is required to pay tiered royalties to the Company at rates beginning in the mid-single-digit percent and increasing up to twenty percent based on the a…
AZN AstraZeneca PLC 92% Reciprocal relationship from AZN graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IRWD graph: Under the collaboration agreement, As…
ASAHI-KASEI-THERAPEUTICS-CORPORATION ASAHI-KASEI-THERAPEUTICS-CORPORATION 85% thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ March 31, Collaborative Arrangements Revenue ​ 2026 ​ ​ ​ 2025 Linaclotide Collaboration and License Agreements: ​ ​ ​ ​ ​ ​ AbbVie (North Ameri…
NEUP Neuphoria Therapeutics Inc. 72% Reciprocal relationship from NEUP graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from NEUP graph: obtain regulatory approvals, manufacture a commercial scale product, or arra…
ZLDPF Zealand Pharma A/S 72% Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from ZLDPF graph: Reciprocal relationship from IRWD graph: Reciprocal relationship from ZLDP…
ZLDPF Zealand Pharma A/S 72% products and to leverage our existing capabilities to develop and commercialize these products in the U.S. We have pursued a partnering strategy for commercializing linaclotide that has allowed us to…

Ironwood Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IRWD-DEBT-10369 Warrants outstanding: 18.82 90% xbrl warrant detail from xbrl 2023-12-31.
IRWD-DEBT Debt stack $597.4M 90% Market cache reports total debt of $597.4M.
IRWD-DEBT-10370 Xbrl Convertible 90% xbrl convertible detail from xbrl 2019-12-31.

Ironwood Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Ironwood Pharmaceuticals, Inc..

Ironwood Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
IRWD-OWNER-ARMISTICE-CAPITAL-LLC ARMISTICE CAPITAL, LLC 90% 13F overlay lists ARMISTICE CAPITAL, LLC as top holder; 227 tracked holders.

Ironwood Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
SLN Silence Therapeutics plc 100.00 2
APRE Aprea Therapeutics, Inc. 100.00 2
DRTS Alpha Tau Medical Ltd. 100.00 2
ARGX argenx SE 100.00 2
TNXP Tonix Pharmaceuticals Holding Corp. 100.00 2
MGNX MacroGenics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
DEO Diageo plc 100.00 2
IDYA IDEAYA Biosciences, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
OLMA Olema Pharmaceuticals, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
ORANY ORANGE 100.00 1 ['supplier']
CCCC C4 Therapeutics, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
MRK Merck & Co., Inc. 100.00 2
View IRWD supply chain intel →

Explore the full interactive supply chain map for Ironwood Pharmaceuticals, Inc..

Open IRWD supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map